AbClon Inc (174900.KQ) stock: key figures, P/E, revenue and dividend

Energy · Coal & Consumable Fuels · South Korea · ISIN KR7174900001

Price
22,050.00 KRW
Market cap
439.36 bn KRW
P/E (2025)
–
P/S (2025)
93.20
Dividend yield
0.00 %
Net margin
-379.86 %
Return on equity (ROE)
-29.63 %
Return on assets (ROA)
-25.31 %

AbClon Inc financials

Fiscal year20242025
Revenue2.34 bn KRW4.71 bn KRW
Gross profit1.08 bn KRW1.14 bn KRW
Operating income-15.59 bn KRW-17.64 bn KRW
EBIT-15.40 bn KRW-17.47 bn KRW
Net income-16.30 bn KRW-17.91 bn KRW
Diluted EPS – continuing operations-935.52 KRW-898.70 KRW

Full history since 2015, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About AbClon Inc

AbClon Inc. engages in the research and development of antibody drugs in South Korea and Sweden. The company's products in pipeline include NEST platform technology products for breast and gastric cancers; AffiMab platform technology products for colon cancer and autoimmune diseases; and CAR-T platform technology products for hematologic and ovarian cancers. AbClon Inc. was founded in 2010 and is based in Seoul, South Korea.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 12.11.2026. Details in the risk notice.